Status:
NOT_YET_RECRUITING
A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic Dermatitis
Lead Sponsor:
Otsuka Pharmaceutical Co., Ltd.
Conditions:
Atopic Dermatitis (AD)
Eligibility:
All Genders
15-70 years
Phase:
PHASE3
Brief Summary
To investigate the superiority of 1% OPA-15406 foam to the vehicle in adult patients with atopic dermatitis (AD).
Eligibility Criteria
Inclusion
- Participants who have been diagnosed AD based on the Diagnostic Criteria for Atopic Dermatitis (Criteria of the Japanese Dermatological Association)
- Participants with a history of AD for at least 3 years
- Participants who have an affected area covering from 5% to 40% of their body surface area (excluding the scalp) at the screening and baseline examinations
- Participants with an IGA score of 2 or 3 at the screening and baseline examinations
Exclusion
- Participants who experienced an acute exacerbation of AD or contact dermatitis within 28 days prior to the baseline examination
- Participants who have been treated with OPA-15406 ointment in the past
Key Trial Info
Start Date :
October 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
156 Patients enrolled
Trial Details
Trial ID
NCT07173478
Start Date
October 1 2025
End Date
December 1 2026
Last Update
September 15 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mita Dermatology Clinic
Tokyo, Japan